Judith Veis, MD, is associate director of Nephrology and Medical Director of Inpatient Dialysis at MedStar Washington Hospital Center. As chair of one of the institutional review boards (IRB) at MedStar Health Research Institute, she is experienced in conducting research and is knowledgeable about IRB policies and procedures. In this role, she is closely involved in the research process, working to help investigators initiate and continue research while promoting the welfare of research participants.
Dr. Veis is a fellow of the American College of Physicians and the American Society of Nephrology. She is certified in Internal Medicine and Nephrology by the American Board of Internal Medicine.The Washington Post Magazine has listed her as a SuperDoc, and Washingtonian Magazine has listed her as a Top Doctor. She is a member of the National Kidney Foundation, and serves on its National Capital Area Professional Advisory Committee and its Research Committee. She is a past president of Women in Nephrology.
Dr. Veis received her medical degree with distinction from Northwestern University School of Medicine in Chicago, where she also completed a residency in Internal Medicine and served as a chief medical resident. She completed a fellowship in Nephrology at the University of Colorado Health Sciences Center, Denver.
Dr. Veis’s research interests includeHyponatremia and other fluid/electrolyte disordersResistant hypertensionPsychosocial factors affecting patients with chronic kidney disease and end-stage renal disease
Effects of tolvaptan vs. fluid restriction in hospitalized patients with dilutional hyponatremia
Dr. Veis was a principal investigator on this hyponatremia trial. This study was designed to determine whether hospitalized patients with symptomatic hyponatremia treated with tolvaptan had shorter hospital stays than patients treated with fluid restriction. The study also tested whether tolvaptan was better than fluid restriction in treating the symptoms of hyponatremia in hospitalized patients.
Cardiovascular outcomes in renal atherosclerotic lesions (CORAL) trial
Dr. Veis was a co-investigator on this trial. In this role, she served as an expert on hypertension, monitoring patients and adjusting medications according to the study protocols and helping patients reach hypertension management targets.
Renal denervation in patients with uncontrolled hypertension (SYMPLICITY Hypertension-3)
Dr. Veis also served as a hypertension expert on this multi-center, prospective, single-blind, randomized, controlled study. This study, sponsored by Medtronic Vascular, was designed to investigate the safety and effectiveness of renal denervation in patients with uncontrolled hypertension.